Northern Trust Corp Talaris Therapeutics, Inc. Transaction History

Northern Trust Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$2.68 - $3.22 $14,600 - $17,542	5,448 Added 21.78%	30,458 $85,000
Q2 2023 Aug 11, 2023	SELL	$1.78 - $3.2 $246,266 - $442,726	-138,352 Reduced 84.69%	25,010 $76,000
Q1 2023 May 15, 2023	SELL	$1.09 - $2.09 $3,605 - $6,913	-3,308 Reduced 1.98%	163,362 $307,000
Q4 2022 Feb 13, 2023	SELL	$0.94 - $1.64 $6,643 - $11,591	-7,068 Reduced 4.07%	166,670 $170,000
Q3 2022 Nov 14, 2022	BUY	$2.3 - $5.03 $25,426 - $55,606	11,055 Added 6.8%	173,738 $457,000
Q2 2022 Aug 12, 2022	SELL	$4.51 - $9.85 $7,482 - $16,341	-1,659 Reduced 1.01%	162,683 $734,000
Q1 2022 May 13, 2022	SELL	$6.89 - $16.56 $25,513 - $61,321	-3,703 Reduced 2.2%	164,342 $1.62 Million
Q4 2021 Feb 08, 2022	BUY	$12.18 - $17.0 $1.04 Million - $1.45 Million	85,058 Added 102.5%	168,045 $2.57 Million
Q3 2021 Nov 15, 2021	SELL	$11.61 - $15.99 $113,743 - $156,654	-9,797 Reduced 10.56%	82,987 $1.13 Million
Q2 2021 Aug 13, 2021	BUY	$12.25 - $18.61 $1.14 Million - $1.73 Million	92,784 New	92,784 $1.36 Million

75.7K

Ticker TALS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,995,900
Market Cap $109M
Description
Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, an...

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

Stay updated on Northern Trust Corp with notifications on news.